Another Major Drug Approval for Regeneron
Congratulations to BCW member Regeneron on the approval of an important new drug to help patients with rheumatoid arthritis. The U.S. Food and Drug Administration has approved the human antibody drug sarilumab, developed by Regeneron Pharmaceuticals Inc. in Westchester and its French pharmaceutical partner Sanofi and trademarked as Kevzara, to treat adult patients with moderately to severely active rheumatoid arthritis.
The FDA approval came less than two months after the federal agency approved Regeneron’s and Sanofi’s human antibody dupilumab, marketed as Dupixent, as the first biologic medicine used to treat the debilitating itching and widespread rashes afflicting adults with moderate to severe cases of atopic dermatitis.
Similar News Items
The BCW and BCW Member Feeding Westchester recently held an important and timely community hunger and budget discussion with Westchester’s State Delegation. The senior team at Feeding Westchester provided the delegation members with an update on the work they did to provide services during the recent government shutdown. With nearly 3 million New […]
Approximately 50 Westchester school officials gathered at Southern Westchester BOCES on November 14 for the School Energy Saving Seminar hosted by the Business Council of Westchester’s (BCW) Clean Energy Action Coalition (CEAC). The morning event presented a deep dive into the energy efficiency programs and funding opportunities available from key state partners: Con Edison, the […]
The complexities of business mergers took center stage on Monday at the Business Council of Westchester’s (BCW) Valley Bank Leadership Conversation. Moderated by BCW President Marsha Gordon, Mergers in Motion: Transforming Organizations through Business Combination invited regional business leaders to share insights drawn from their experiences as strategic acquirers, owner-sellers, and trusted advisors. The event […]
Become A Member
Join the county’s largest and most influential business organization today.
JOIN NOW!
Leave a Comment
You must be logged in to post a comment.